Hypertrophic growth is an adaptive response of the heart to diverse pathological stimuli and is characterized by cardiomyocyte enlargement, protein synthesis, and activation of a foetal programme of cardiac gene expression [1] [2] [3] [4] . Cardiomyocyte enlargement is also known to occur without upregulation of foetal genes during, for example, exercise-and thyroid-induced cardiac hypertrophy [5, 6] . The development of the hypertrophic phenotype is manifested by a coordinated series of events, where several transcription factors are activated in response to different hypertrophic agents [7] [8] [9] . Cardiac hypertrophy is also associated with hyperactivity of the sympathetic nervous system as well as elevated levels of plasma norepinephrine (NE) [10] . In fact, NE is known to produce cardiac hypertrophy [11] [12] [13] , which may, in part, be mediated via the activation of ␣1-adrenoceptors (␣1-AR) [14] [15] [16] [17] 
natriuretic factor (ANF) expression and protein synthesis, was due to activation of phospholipase C (PLC) via the ␣1-AR
. We have also reported that activity of PLC isozymes regulate their own gene expression [14] , which might represent a cycle of events that perpetuates the hypertrophic response to NE. (NE) [24] .
Furthermore, by using different pharmacological agents, we have demonstrated that c-Fos and c-Jun gene expression is regulated by PLC activity in adult cardiomyocytes through a protein kinase C (PKC)-and extracellular regulated kinases (ERK) 1/2-dependent pathway in response to

However, the identity of the specific PLC isozymes involved in the regulation of c-Fos and c-Jun gene expression as well as the role of these transcription factors in the regulation of PLC isozyme gene expression in adult cardiomyocytes is not known. Therefore, by employing a gene silencing approach, this study was undertaken to determine which PLC isozyme regulates the expression of c-Fos and c-Jun and to determine if c-Fos and c-Jun are involved in the regulation of PLC isozyme gene expression in response to NE in adult cardiomyocytes.
Materials and methods
Cardiomyocyte isolation and stimulation
All experimental protocols for animal studies were approved by the Animal Care Committee of the University of Manitoba, in accordance with the guidelines established by the Canadian Council on Animal Care. Left ventricle (LV) cardiomyocytes were isolated from male Sprague-Dawley rats
(250-300 g) as previously described [14, 15] . The cells were incubated with 5 M NE for 2 hrs for gene expression; this concentration and time of incubation were previously determined to be optimal [14] . 
Silencing of c-Fos, c-Jun and PLC isozyme genes by small interfering (si) RNA
RNA isolation and semi-quantitative PCR
Total RNA was isolated from LV myocytes using RNA isolation kit (Life Technologies, ON, Canada), as described [14, 15] 
Western blot analysis
Total membrane proteins (20 g ) and high molecular weight marker (BioRad, Hercules, CA, USA) were separated on SDS-PAGE as described previously [14, [24] [25] [26] [25, 26] . (Fig. 3) . 
Statistical analysis
Regulation of c-Fos and c-Jun gene expression in response to NE in cardiomyocytes transfected with PLC isozyme siRNA
To examine the involvement of specific PLC isozymes in the NEinduced increases in c-Fos, c-Jun gene expression, cardiomyocytes were genetically manipulated to silence PLC isozyme genes with si RNA. Transfection of cardiomyocytes with PLC ␤1, ␤3 and ␦1 si RNA inhibited the NE-induced increases in c-Fos and c-Jun gene expression, whereas PLC ␥1 gene silencing did not affect the activation of c-Fos and c-Jun gene expression in response to NE
Regulation of PLC isozyme gene expression, protein content and activity by c-Fos and c-Jun siRNA
While a pharmacological approach was previously used to examine the role of c-Fos and c-Jun in regulating PLC isozyme gene expression in response to NE [24], the involvement of transcription factors, c-Fos and c-Jun was further examined in cardiomyocytes genetically manipulated to silence c-Fos and c-Jun gene. Again, transfection of cardiomyocytes with c-Fos and c-Jun siRNA
Discussion
Although by using different pharmacological agents we have reported earlier that PLC activity is involved in the regulation of transcription factor, c-Fos and c-Jun gene expression [24], we have now shown in this study that specific PLC isozyme activity regulate c-Fos and c-Jun gene expression in response to NE in adult cardiomyocytes. Because concomitant increases in PLC isozyme, c-Jun and c-Fos mRNA levels have been observed in response to NE, the relationship between these transcription factors and PLC isozyme gene expression was further investigated.
The specific knockdown of PLC ␤1, ␤3, and ␦1 with siRNA and [27] and is reported to regulate ANF gene expression [28] [29] [30] [31] , is activated primarily through tyrosine phosphorylation [29] . However, it is interesting to note that a link between Gq and tyrosine kinase provides a mechanism for the ␣1-AR mediated activation of PLC ␥ [4, 32] . [33] and continued increase in ANF is related to increases in c-Fos and c-Jun expression [28] . It is also interesting to note that the overexpression of c-Jun has been reported to result in an increase in the transcription of ANF [34, 35] 
Fig. 3 Inhibition of norepinephrine-induced increases in c-Fos and c-Jun mRNA levels in cardiomyocytes transfected with PLC isozymes siRNA. Representative blots (A) and quantified data (B) and (C) showing c-Fos (74 bp) and c-Jun
subsequent attenuation of their protein content and activity prevented the NE-induced increases in c-Fos and c-Jun gene expression, indicating the involvement of PLC ␤1, ␤3 and ␦1 isozyme activity in the regulation of c-Fos and c-Jun gene expression. It is interesting to note that knockdown of PLC ␥1 did not prevent the NE-induced increase in the expression of c-Fos and c-Jun genes, although it prevented the increase in ANF gene expression and protein synthesis in response to NE. It could be inferred that PLC ␥1 may be involved in a signal transduction pathway, independent of c-Fos and c-Jun, which regulates ANF gene expression as well as protein synthesis. A possible candidate in this pathway could be the early growth response factor-1 (Egr-1), the expression of which is known to be induced in response to ␣1-AR stimulation
Thus, while NE was seen to activate all PLC isozymes in this study, the ␣1-AR may display a discrete requirement for PLC ␥1 that does not involve the regulation of c-Fos and c-Jun
Fig. 4 Prevention of the norepinephrineinduced increases in c-Fos and c-
. Thus, we consider that the NEinduced increase in c-Fos/c-Jun, which is involved in mediating NE-induced cardiac hypertrophic response, is also characterized by increases in the gene expression of specific PLC isozymes and concomitant increases in protein levels as well as activity. Furthermore, while it is already known that PLC is upstream of c-Fos/c-Jun and ANF, our data also seem to suggest that in the signaling pathway mediated by NE, activation of c-Fos and c-Jun is upstream of ANF.
The c-Fos and c-Jun proteins form the activator protein-1 (AP-1), which is a transcription factor considered to be involved in cardiac hypertrophy [16, 36, 37] . Taimor et al. [16] [22] . On the basis of our earlier [11, 12] [16, 29, 39, 40] , it is likely that the mechanism of action of prazosin would include prevention of the activation of PLC and subsequent signal transduction events regulating the early response genes, associated with cardiac hypertrophy. It should be mentioned that in addition to the activation of the sympathetic nervous system, activation of the renin-angiotensin system is also known to occur during the development of cardiac hypertrophy [41] . Angiotensin II (ANG II) can initiate cardiac hypertrophy and upregulate PLC ␤3 [42, 43] as well as increase the expression of c-Fos and c-Jun [44] . Losartan, an ANG II type 1 receptor blocker has also been reported to regress cardiac hypertrophy [40, 45, 46] ; an effect that may, in part, be due to an inhibition of the upregulation of PLC Fig. 8 isozymes [43, 47] . It should also be noted that the activation of specific PLC isozymes occur in pressure [48] and volume [25] overloaded hypertrophied heart. Taken together, this study supports the view that the activation of PLC isozymes is considered to be an important step in cardiac hypertrophy and thus may be a target for its prevention. 
